Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas

Anticancer Research

Volumn 25, Issue 6 A, 2005, Pages 3771-3776

  Katano, Mitsou ^a   Morisaki, Takahashi ^a   Koga, Kennichiro ^a   Nakamura, Mitsunari ^b   Onishi, Hideya ^a   Matsumoto, Kotaro ^a   Tasaki, Akira ^a   Nakashima, Hiroshi ^a   Akiyoshi, Takahashi ^a   Nakamura, Masafumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Sada Hospital   (Japan)

Author keywords

Activated lymphocytes; Autologous tumor cells; Dendritic cells; Vaccine

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DUPAN 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY CD3; OKT 3; PICIBANIL; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 4; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIGENICITY; AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DISSEMINATED CANCER; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FEVER; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LEUKOCYTE ACTIVATION; LYMPHOCYTE ACTIVATION; MALE; METASTASIS; OUTCOMES RESEARCH; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUPERNATANT; SURVIVAL RATE; TUMOR CELL; TUMOR CELL PULSED DENDRITIC CELL VACCINE THERAPY;

ADULT; AGED; CANCER VACCINES; CARCINOMA; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MUROMONAB-CD3; NEOPLASMS;

EID: 27844440976     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Morisaki T, Matsumoto K, Onishi H, Kuroli H, Baba E, Tasaki A, Kubo M, Nakamura M, Inaba S, Yamaguchi K, Tanaka M and Katano M: Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives. Hum Cell 16: 175-182, 2003
2. Banchereau J, Paczesny S, Blanco P, Bennett L, Pascual V, Fay J and Palucka AK: Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann N Y Acad Sci 987: 180-187, 2003.
3. Banchercau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B and Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811, 2000.
4. Lopez JA and Hart DN: Current issues in dendritic cell cancer immunotherapy. Curr Opin Mol Ther 4: 54-63, 2002.
5. Asavaroengchai W, Korera Y and Mule JJ: Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci USA 99: 931-936, 2002.
6. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W, Prins RM and Black KL: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits system cytotoxicity and intracranial T-cell infiltration. Cancer Res 61: 842-847, 2001.
7. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT and Falo LD Jr: Peptide-pulsed dendritic cells induce antigen specific CTL-mediated protective tumor immunity. J Exp Med 183: 283-287, 1996.
8. Boczkowski D, Nair SK, Snyder D and Gilboa E: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184: 465-472, 1996.
9. Velders MP, Nieland JD, Rudolf MP, Loviscek K, Weijzen S, de Visser KE, Macedo MF, Carbone M and Kast WM: Identification of peptides for immunotherapy of cancer. It is still worth the effort. Crit Rev Immunol 18: 7-27, 1998.
10. Boland CR and Ricciardiello L: How many mutations does it take to make a tumor? Proc Natl Acad Sci USA 96: 14675-14677, 1999.
11. Berard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, Taquet N, Rimoldi D, Cerottini JC, Banchereau J and Palucka AK: Cross-priming of naïve CDS T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 192: 1535-1544, 2000.
12. Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Chang A and Mule J: Treatment of solid tumours in children with tumor-lysate-pulsed dendritic cells. Lancet 356: 1163-1165, 2000.
13. Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, Lee PP, Geiger JD and Mule JJ: A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 8: 1021-1032, 2002.
14. Kuroki H, Morisaki T, Matsumoto K, Onishi H, Baba E, Tanaka M and Katano M: Streptococcal preparation OK-432: a new maturation factor of monocyte-derived dendritic cells for clinical use. Cancer Immunol Immunother 52: 561-568, 2003.
15. Versteegen J, Logtenberg T and Ballieux R: IFN-gamma-producing human lymphocytes by spot-ELISA. A method to detect lymphokine-producing lymphocytes at the single-cell level. J Immunol Methods 111: 25-29, 1988.
16. Onishi H, Morisaki T, Baba E, Kuga H, Kuroki H, Matsumoto K, Tanaka M and Katano M: Dysfunctional and short-lived subsets in monocyte-derived dendritic cells from patients with advanced cancer. Clin Immunol 105: 286-295, 2002.
17. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N and Schuler G: Rapid induction of tumor specific Type 1 helper cells in metastatic melanoma patients by vaccination with mature cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 795: 1279-1288, 2002.